GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Days Inventory

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Days Inventory : 0.00 (As of Sep. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Intercept Pharmaceuticals's Average Total Inventories for the three months ended in Sep. 2023 was $0.0 Mil. Intercept Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.2 Mil. Hence, Intercept Pharmaceuticals's Days Inventory for the three months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for Intercept Pharmaceuticals's Days Inventory or its related term are showing as below:

ICPT's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 192.63
* Ranked among companies with meaningful Days Inventory only.

Intercept Pharmaceuticals's Days Inventory stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Intercept Pharmaceuticals's Inventory-to-Revenue for the three months ended in Sep. 2023 was 0.00.


Intercept Pharmaceuticals Days Inventory Historical Data

The historical data trend for Intercept Pharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Days Inventory Chart

Intercept Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intercept Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intercept Pharmaceuticals's Days Inventory

For the Biotechnology subindustry, Intercept Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intercept Pharmaceuticals's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Days Inventory falls into.



Intercept Pharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Intercept Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2022 is calculated as

Days Inventory (A: Dec. 2022 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2021 ) + Total Inventories (A: Dec. 2022 )) / count ) / Cost of Goods Sold (A: Dec. 2022 )*Days in Period
=( (0 + 0) / 1 ) / 0.98399999999998*365
=0 / 0.98399999999998*365
=0.00

Intercept Pharmaceuticals's Days Inventory for the quarter that ended in Sep. 2023 is calculated as:

Days Inventory (Q: Sep. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Jun. 2023 ) + Total Inventories (Q: Sep. 2023 )) / count ) / Cost of Goods Sold (Q: Sep. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0.197*365 / 4
=0 / 0.197*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intercept Pharmaceuticals  (NAS:ICPT) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Intercept Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2023 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Intercept Pharmaceuticals's Inventory to Revenue for the three months ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Intercept Pharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Intercept Pharmaceuticals (Intercept Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
305 Madison Avenue, Morristown, NJ, USA, 07960
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Executives
Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandip Kapadia officer: CFO and Treasurer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jason Campagna officer: Chief Medical Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Francesco Micheli 10 percent owner C/O GENEXTRA S.P.A., VIA G. DE GRASSI, 11, MILAN L6 20124
Genextra S.p.a. 10 percent owner VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Headlines

From GuruFocus